|
1
|
Chen SC, Huang JC, Su HM, Chiu YW, Chang
JM, Hwang SJ and Chen HC: Prognostic cardiovascular markers in
chronic kidney disease. Kidney Blood Press Res. 43:1388–1407. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham MW Jr and LaMarca B: Risk of
cardiovascular disease, end-stage renal disease, and stroke in
postpartum women and their fetuses after a hypertensive pregnancy.
Am J Physiol Regul Integr Comp Physiol. 315:R521–R528. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah SR and Winchester DE: The impact of
chronic kidney disease on medication choice and pharmacologic
management in patients with heart failure. Expert Rev Clin
Pharmacol. 11:571–579. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siedlecki AM, Jin X and Muslin AJ: Uremic
cardiac hypertrophy is reversed by rapamycin but not by lowering of
blood pressure. Kidney Int. 75:800–808. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sethna CB, Merchant K and Reyes A:
Cardiovascular disease risk in children with kidney disease. Semin
Nephrol. 38:298–313. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim H, Yoo TH, Choi KH, Oh KH, Lee J, Kim
SW, Kim TH, Sung S and Han SH; KNOW-CKD Group, : Baseline
cardiovascular characteristics of adult patients with chronic
kidney disease from the korean cohort study for outcomes in
patients with chronic kidney disease (KNOW-CKD). J Korean Med Sci.
32:231–239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lash JP, Go AS, Appel LJ, He J, Ojo A,
Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, et al: Chronic
Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics
and associations with kidney function. Clin J Am Soc Nephrol.
4:1302–1311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao H and Liu S: Role of uremic toxin
indoxyl sulfate in the progression of cardiovascular disease. Life
Sci. 185:23–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang K, Wang C, Nie L, Zhao X, Gu J, Guan
X, Wang S, Xiao T, Xu X, He T, et al: Klotho protects against
indoxyl sulphate-induced myocardial hypertrophy. J Am Soc Nephrol.
26:2434–2446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang K, Xu X, Nie L, Xiao T, Guan X, He T,
Yu Y, Liu L, Huang Y, Zhang J and Zhao J: Indoxyl sulfate induces
oxidative stress and hypertrophy in cardiomyocytes by inhibiting
the AMPK/UCP2 signaling pathway. Toxicol Lett. 234:110–119. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Six I, Gross P, Rémond MC, Chillon JM,
Poirot S, Drueke TB and Massy ZA: Deleterious vascular effects of
indoxyl sulfate and reversal by oral adsorbent AST-120.
Atherosclerosis. 243:248–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshifuji A, Wakino S, Irie J, Matsui A,
Hasegawa K, Tokuyama H, Hayashi K and Itoh H: Oral adsorbent
AST-120 ameliorates gut environment and protects against the
progression of renal impairment in CKD rats. Clin Exp Nephrol.
22:1069–1078. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kamiński T, Michałowska M and Pawlak D:
Aryl hydrocarbon receptor (AhR) and its endogenous agonist-indoxyl
sulfate in chronic kidney disease. Postepy Hig Med Dosw (Online).
71:624–632. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wheeler MA, Rothhammer V and Quintana FJ:
Control of immune-mediated pathology via the aryl hydrocarbon
receptor. J Biol Chem. 292:12383–12389. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Dhfyan A, Alhoshani A and Korashy HM:
Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates
breast cancer stem cells expansion through PTEN inhibition and
β-Catenin and Akt activation. Mol Cancer. 16:142017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Korashy HM and El-Kadi AO: The role of
aryl hydrocarbon receptor in the pathogenesis of cardiovascular
diseases. Drug Metab Rev. 38:411–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Sherbeni AA and El-Kadi AO: Repurposing
resveratrol and Fluconazole to modulate human cytochrome
P450-mediated arachidonic acid metabolism. Mol Pharm. 13:1278–1288.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yaghini FA, Song CY, Lavrentyev EN,
Ghafoor HU, Fang XR, Estes AM, Campbell WB and Malik KU:
Angiotensin II-induced vascular smooth muscle cell migration and
growth are mediated by cytochrome P450 1B1-dependent superoxide
generation. Hypertension. 55:1461–1467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Althurwi HN, Tse MM, Abdelhamid G, Zordoky
BN, Hammock BD and El-Kadi AO: Soluble epoxide hydrolase inhibitor,
TUPS, protects against isoprenaline-induced cardiac hypertrophy. Br
J Pharmacol. 168:1794–1807. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elkhatali S, Maayah Z, El-Sherbeni AA,
Elshenawy OH, Abdelhamid G, Shoieb SM and El-Kadi AOS: Inhibition
of Mid-chain HETEs protects against angiotensin II-induced cardiac
hypertrophy. J Cardiovasc Pharmacol. 70:16–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maayah ZH, Althurwi HN, El-Sherbeni AA,
Abdelhamid G, Siraki AG and El-Kadi AO: The role of cytochrome P450
1B1 and its associated mid-chain hydroxyeicosatetraenoic acid
metabolites in the development of cardiac hypertrophy induced by
isoproterenol. Mol Cell Biochem. 429:151–165. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gondouin B, Cerini C, Dou L, Sallée M,
Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N,
Poitevin S, et al: Indolic uremic solutes increase tissue factor
production in endothelial cells by the aryl hydrocarbon receptor
pathway. Kidney Int. 84:733–744. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pang X, He G, Luo C, Wang Y and Zhang B:
Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in
esophageal cancer cells. Tumour Biol. 37:963–970. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deltombe O, Van Biesen W, Glorieux G,
Massy Z, Dhondt A and Eloot S: Exploring protein binding of uremic
toxins in patients with different stages of chronic kidney disease
and during hemodialysis. Toxins (Basel). 7:3933–3946. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Adesso S, Popolo A, Bianco G, Sorrentino
R, Pinto A, Autore G and Marzocco S: The uremic toxin indoxyl
sulphate enhances macrophage response to LPS. PLoS One.
8:e767782013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jennings BL, Montanez DE, May ME Jr, Estes
AM, Fang XR, Yaghini FA, Kanu A and Malik KU: Cytochrome P450 1B1
contributes to increased blood pressure and cardiovascular and
renal dysfunction in spontaneously hypertensive rats. Cardiovasc
Drugs Ther. 28:145–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jennings BL, George LW, Pingili AK, Khan
NS, Estes AM, Fang XR, Gonzalez FJ and Malik KU: Estrogen
metabolism by cytochrome P450 1B1 modulates the hypertensive effect
of angiotensin II in female mice. Hypertension. 64:134–140. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pingili AK, Thirunavukkarasu S, Kara M,
Brand DD, Katsurada A, Majid DS, Navar LG, Gonzalez FJ and Malik
KU: 6β-hydroxytestosterone, a cytochrome P450
1B1-testosterone-metabolite, mediates angiotensin II-induced renal
dysfunction in male mice. Hypertension. 67:916–926. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jennings BL, Anderson LJ, Estes AM, Fang
XR, Song CY, Campbell WB and Malik KU: Involvement of cytochrome
P-450 1B1 in renal dysfunction, injury, and inflammation associated
with angiotensin II-induced hypertension in rats. Am J Physiol
Renal Physiol. 302:F408–F420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li F, Zhu W and Gonzalez FJ: Potential
role of CYP1B1 in the development and treatment of metabolic
diseases. Pharmacol Ther. 178:18–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
D'Uva G, Baci D, Albini A and Noonan DM:
Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a
target in the tumor and the microenvironment. Cancer Treat Rev.
63:1–18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moghadam AR, Mehramiz M, Entezari M,
Aboutalebi H, Kohansal F, Dadjoo P, Fiuji H, Nasiri M, Aledavood
SA, Anvari K, et al: A genetic polymorphism in the CYP1B1 gene in
patients with squamous cell carcinoma of the esophagus: An Iranian
Mashhad cohort study recruited over 10 years. Pharmacogenomics.
19:539–546. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gu CY, Li GX, Zhu Y, Xu H, Zhu Y, Qin XJ,
Bo D and Ye DW: A single nucleotide polymorphism in CYP1B1 leads to
differential prostate cancer risk and telomere length. J Cancer.
9:269–274. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tse MM, Aboutabl ME, Althurwi HN,
Elshenawy OH, Abdelhamid G and El-Kadi AO: Cytochrome P450
epoxygenase metabolite, 14,15-EET, protects against
soproterenol-induced cellular hypertrophy in H9c2 rat cell line.
Vasc Pharmacol. 58:363–373. 2013. View Article : Google Scholar
|
|
36
|
Thum T and Borlak J: Testosterone,
cytochrome P450, and cardiac hypertrophy. FASEB J. 16:1537–1549.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maayah ZH and El-Kadi AO: The role of
mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of
hypertension and cardiac hypertrophy. Arch Toxicol. 90:119–136.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Evans M, Grams ME, Sang Y, Astor BC,
Blankestijn PJ, Brunskill NJ, Collins JF, Kalra PA, Kovesdy CP,
Levin A, et al: Risk Factors for Prognosis in Patients With
Severely Decreased GFR. Kidney Int Rep. 3:625–637. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Savira F, Magaye R, Hua Y, Liew D, Kaye D,
Marwick T and Wang BH: Molecular mechanisms of protein-bound uremic
toxin-mediated cardiac, renal and vascular effects: Underpinning
intracellular targets for cardiorenal syndrome therapy. Toxicol
Lett. 308:34–49. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo J, Lu L, Hua Y, Huang K, Wang I, Huang
L, Fu Q, Chen A, Chan P, Fan H, et al: Vasculopathy in the setting
of cardiorenal syndrome: Roles of protein-bound uremic toxins. Am J
Physiol Heart Circ Physiol. 313:H1–H13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Niwa T: Uremic toxicity of indoxyl
sulfate. Nagoya J Med Sci. 72:1–11. 2010.PubMed/NCBI
|
|
42
|
Barreto FC, Barreto DV, Liabeuf S, Meert
N, Glorieux G, Temmar M, Choukroun G, Vanholder R and Massy ZA:
European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is
associated with vascular disease and mortality in chronic kidney
disease patients. Clin J Am Soc Nephrol. 4:1551–1558. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lekawanvijit S, Adrahtas A, Kelly DJ,
Kompa AR, Wang BH and Krum H: Does indoxyl sulfate, a uraemic
toxin, have direct effects on cardiac fibroblasts and myocytes? Eur
Heart J. 31:1771–1779. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fujii H, Nishijima F, Goto S, Sugano M,
Yamato H, Kitazawa R, Kitazawa S and Fukagawa M: Oral charcoal
adsorbent (AST-120) prevents progression of cardiac damage in
chronic kidney disease through suppression of oxidative stress.
Nephrol Dial Transplant. 24:2089–2095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brito JS, Borges NA, Esgalhado M, Magliano
DC, Soulage CO and Mafra D: Aryl hydrocarbon receptor activation in
chronic kidney disease: Role of Uremic Toxins. Nephron. 137:1–7.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Asai H, Hirata J and Watanabe-Akanuma M:
Indoxyl glucuronide, a protein-bound uremic toxin, inhibits
hypoxia-inducible factor-dependent erythropoietin expression
through activation of aryl hydrocarbon receptor. Biochem Biophys
Res Commun. 504:538–544. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ito S, Osaka M, Edamatsu T, Itoh Y and
Yoshida M: Crucial role of the aryl hydrocarbon receptor (AhR) in
indoxyl sulfate-induced vascular inflammation. J Atheroscler
Thromb. 23:960–975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barisione C, Ghigliotti G, Canepa M, Balbi
M, Brunelli C and Ameri P: Indoxyl sulfate: A candidate target for
the prevention and treatment of cardiovascular disease in chronic
kidney disease. Curr Drug Targets. 16:366–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Esser C and Rannug A: The aryl hydrocarbon
receptor in barrier organ physiology, immunology, and toxicology.
Pharmacol Rev. 67:259–279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang N and Walker MK: Crosstalk between
the aryl hydrocarbon receptor and hypoxia on the constitutive
expression of cytochrome P4501A1 mRNA. Cardiovasc Toxicol.
7:282–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ramezan A, Massy ZA, Meijers B, Evenepoel
P, Vanholder R and Raj D: Role of the gut microbiome in uremia: A
potential therapeutic target. Am J Kidney Dis. 67:483–498. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dou L, Sallée M, Cerini C, Poitevin S,
Gondouin B, Jourde-Chiche N, Fallague K, Brunet P, Calaf R, Dussol
B, et al: The cardiovascular effect of the uremic solute indole-3
acetic acid. J Am Soc Nephrol. 26:876–887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lund AK, Goens MB, Nuñez BA and Walker MK:
Characterizing the role of endothelin-1 in the progression of
cardiac hypertrophy in aryl hydrocarbon receptor (AhR) null mice.
Toxicol Appl Pharmacol. 212:127–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fernandez-Salguero PM, Ward JM, Sundberg
JP and Gonzalez FJ: Lesions of aryl-hydrocarbon receptor-deficient
mice. Vet Pathol. 34:605–614. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang Q, Chen J, Ko CI, Fan Y, Carreira V,
Chen Y, Xia Y, Medvedovic M and Puga A: Disruption of aryl
hydrocarbon receptor homeostatic levels during embryonic stem cell
differentiation alters expression of homeobox transcription factors
that control cardiomyogenesis. Environ Health Perspect.
121:1334–1343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zordoky BN and El-Kadi AO: Effect of
cytochrome P450 polymorphism on arachidonic acid metabolism and
their impact on cardiovascular diseases. Pharmacol Ther.
125:446–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Amara IE, Elshenawy OH, Abdelrady M and
El-Kadi AO: Acute mercury toxicity modulates cytochrome P450,
soluble epoxide hydrolase and their associated arachidonic acid
metabolites in C57Bl/6 mouse heart. Toxicol Lett. 226:53–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kaur-Knudsen D, Bojesen SE and
Nordestgaard BG: Cytochrome P450 1B1 and 2C9 genotypes and risk of
ischemic vascular disease, cancer, and chronic obstructive
pulmonary disease. Curr Vasc Pharmacol. 10:512–520. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
El-Sherbeni AA and El-Kadi AO: Alterations
in cytochrome P450-derived arachidonic acid metabolism during
pressure overload-induced cardiac hypertrophy. Biochem Pharmacol.
87:456–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Malik KU, Jennings BL, Yaghini FA,
Sahan-Firat S, Song CY, Estes AM and Fang XR: Contribution of
cytochrome P450 1B1 to hypertension and associated pathophysiology:
A novel target for antihypertensive agents. Prostaglandins Other
Lipid Mediat. 98:69–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ravarotto V, Simioni F, Pagnin E, Davis PA
and Calò LA: Oxidative stress-chronic kidney disease-cardiovascular
disease: A vicious circle. Life Sci. 210:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
